WO2005047899A3 - Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations - Google Patents

Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations Download PDF

Info

Publication number
WO2005047899A3
WO2005047899A3 PCT/US2004/036952 US2004036952W WO2005047899A3 WO 2005047899 A3 WO2005047899 A3 WO 2005047899A3 US 2004036952 W US2004036952 W US 2004036952W WO 2005047899 A3 WO2005047899 A3 WO 2005047899A3
Authority
WO
WIPO (PCT)
Prior art keywords
fprl1
inflammation
pain
tool
treatment
Prior art date
Application number
PCT/US2004/036952
Other languages
English (en)
Other versions
WO2005047899A2 (fr
Inventor
Norman Nash
Audra L Scully
Luis Gardell
Roger Olsson
Magnus Gustafsson
Original Assignee
Acadia Pharm Inc
Norman Nash
Audra L Scully
Luis Gardell
Roger Olsson
Magnus Gustafsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc, Norman Nash, Audra L Scully, Luis Gardell, Roger Olsson, Magnus Gustafsson filed Critical Acadia Pharm Inc
Priority to AU2004290368A priority Critical patent/AU2004290368A1/en
Priority to CA002544983A priority patent/CA2544983A1/fr
Priority to EP04810415A priority patent/EP1692502A2/fr
Priority to JP2006539672A priority patent/JP2007516434A/ja
Priority to BRPI0416272-2A priority patent/BRPI0416272A/pt
Publication of WO2005047899A2 publication Critical patent/WO2005047899A2/fr
Publication of WO2005047899A3 publication Critical patent/WO2005047899A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Manufacturing & Machinery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ceramic Engineering (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Materials Engineering (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)

Abstract

L'invention concerne des composés qui activent de manière sélective le récepteur FPRL1. L'invention concerne également des procédés destinés à soulager des réactions inflammatoires par régulation d'étapes clés dans le commerce illicite de leucocytes et dans la prévention de dommages tissulaires induits par des neutrophiles par administration à un sujet d'une quantité efficace sur le plan thérapeutique des composés de cette invention. En outre, cette invention concerne des procédés de modulation ou de production d'une action agoniste spécifique du récepteur FPRL1 par administration d'une quantité efficace des composés susmentionnés.
PCT/US2004/036952 2003-11-07 2004-11-04 Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations WO2005047899A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2004290368A AU2004290368A1 (en) 2003-11-07 2004-11-04 Use of the lipoxin receptor, FPRL1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CA002544983A CA2544983A1 (fr) 2003-11-07 2004-11-04 Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations
EP04810415A EP1692502A2 (fr) 2003-11-07 2004-11-04 Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations
JP2006539672A JP2007516434A (ja) 2003-11-07 2004-11-04 リポキシン受容体ｆｐｒｌ１の、疼痛および炎症の治療に有効な化合物を識別する手段としての使用
BRPI0416272-2A BRPI0416272A (pt) 2003-11-07 2004-11-04 usos do receptor fprl1, e de compostos, uso profilático de compostos, métodos de triagem para um composto capaz de afetar uma ou mais atividades de um receptor fprl1, de tratamento ou prevenção de inflamação, de identificação de um composto de indução de vasodilatação, para antagonismo de uma resposta vasoconstrutiva a um sulfidopeptìdeo leucotrieno em um indivìduo, e para estimulação de proliferação celular em um indivìduo, e, composto

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51847603P 2003-11-07 2003-11-07
US60/518,476 2003-11-07
US51908503P 2003-11-10 2003-11-10
US60/519,085 2003-11-10
US59292604P 2004-07-30 2004-07-30
US60/592,926 2004-07-30

Publications (2)

Publication Number Publication Date
WO2005047899A2 WO2005047899A2 (fr) 2005-05-26
WO2005047899A3 true WO2005047899A3 (fr) 2006-03-30

Family

ID=34595924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036952 WO2005047899A2 (fr) 2003-11-07 2004-11-04 Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations

Country Status (7)

Country Link
EP (1) EP1692502A2 (fr)
JP (1) JP2007516434A (fr)
KR (1) KR20060130064A (fr)
AU (1) AU2004290368A1 (fr)
BR (1) BRPI0416272A (fr)
CA (1) CA2544983A1 (fr)
WO (1) WO2005047899A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101724765B1 (ko) 2009-05-18 2017-04-07 액테리온 파마슈티칼 리미티드 Ａｌｘ 수용체 및/또는 ｆｐｒｌ2 아고니스트로서의 브릿지 스피로［2.4］헵탄 유도체

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003023007A2 (fr) 2001-09-07 2003-03-20 Bristol-Myers Squibb Company Polynucleotide codant pour un recepteur lie a une nouvelle proteine g humaine, hgprmby39
US20100291089A1 (en) * 2005-07-07 2010-11-18 Postech Academy-Industry Foundation Ligand of regulating immune response, and use thereof in treating an immune response-related disease
AR069650A1 (es) * 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
TWI434685B (zh) * 2007-12-18 2014-04-21 Actelion Pharmaceuticals Ltd 胺基三唑衍生物
EP2440555B1 (fr) 2009-06-09 2016-05-18 Actelion Pharmaceuticals Ltd Dérivés fluorés de l'aminotriazole
KR20120046159A (ko) 2009-06-12 2012-05-09 액테리온 파마슈티칼 리미티드 Ａｌｘ 수용체 아고니스트로서의 옥사졸 및 티아졸 유도체
ES2553635T3 (es) 2010-11-17 2015-12-10 Actelion Pharmaceuticals Ltd. Derivados de éster spiro[2.4]heptano puenteados
AU2011336973A1 (en) * 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
US9346793B2 (en) 2010-12-07 2016-05-24 Actelion Pharmaceuticals, Ltd. Hydroxylated aminotriazole derivatives as ALX receptor agonists
WO2012077049A1 (fr) 2010-12-07 2012-06-14 Actelion Pharmaceuticals Ltd Dérivés d'oxazolyl-méthyléther convenant comme agonistes du récepteur alx
AU2012214265A1 (en) * 2011-02-11 2013-09-05 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2770989B1 (fr) * 2011-10-26 2018-09-05 Allergan, Inc. Dérivés amides d'acides aminés substitués par une n-urée à titre de modulateurs des récepteurs de type 1 du peptide formyle (fprl-1)
EP2597160B1 (fr) 2011-11-23 2015-09-23 Universita' Degli Studi "G. d'Annunzio" Chieti-Pescara Outil de criblage pour la découverte de médicament anti-inflammatoire comportant le promoteur de gène FPR2/ALX
US9284288B2 (en) 2012-05-16 2016-03-15 Actelion Pharmaceuticals Ltd. 1-(p-tolyl) cyclopropyl substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
BR122017004254B1 (pt) 2013-03-06 2021-04-13 Allergan, Inc. Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
WO2014204229A2 (fr) * 2013-06-21 2014-12-24 성균관대학교산학협력단 Composition pharmaceutique pour la prévention ou le traitement de l'arthrite rhumatoïde, comprenant un peptide en tant que principe actif
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
EP3022174B1 (fr) * 2013-07-16 2018-09-05 Allergan, Inc. Dérivés d'acides aminés substitués par une n-urée utilisés comme modulateurs des récepteurs des peptides formylés
KR20160033747A (ko) 2013-07-18 2016-03-28 액테리온 파마슈티칼 리미티드 Ａｌｘ 수용체 아고니스트로서의 피페라진 치환된 브릿지연결 스피로［２．４］헵탄 유도체
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
NZ720508A (en) 2013-11-28 2019-03-29 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
CA2948876A1 (fr) 2014-05-21 2015-11-26 Allergan, Inc. Derives d'imidazole en tant que modulateurs des recepteurs de peptide formyle
CN107849049B (zh) 2015-05-27 2021-03-16 杏林制药株式会社 脲衍生物或其药用盐
US10858314B2 (en) 2015-05-27 2020-12-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
KR101731303B1 (ko) 2015-06-11 2017-05-02 가톨릭대학교 산학협력단 인터루킨―1베타 억제제의 스크리닝 방법
EA202092094A1 (ru) 2018-03-05 2020-12-10 Бристол-Маерс Сквибб Компани Фенилпирролидиноновые агонисты формилпептидного рецептора 2
IT202100004964A1 (it) * 2021-03-03 2022-09-03 Univ Degli Studi Di Bari Aldo Moro Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031261A2 (fr) * 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methodes et compositions d'identification d'effecteurs de recepteurs
WO2001057074A1 (fr) * 2000-02-04 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands des recepteurs de la classe fpr qui induisent une reponse immunitaire de l'hote a un agent pathogene ou inhibent l'infection par le vih
WO2003074069A2 (fr) * 2002-03-07 2003-09-12 Bayer Healthcare Ag Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1)
WO2003106683A1 (fr) * 2002-06-14 2003-12-24 武田薬品工業株式会社 Procede de criblage
WO2004027427A1 (fr) * 2002-09-19 2004-04-01 Astrazeneca Ab Analyse de ligands fprl-1
WO2005024057A1 (fr) * 2003-09-10 2005-03-17 Galapagos Genomics N.V. Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031261A2 (fr) * 1998-11-25 2000-06-02 Cadus Pharmaceutical Corporation Methodes et compositions d'identification d'effecteurs de recepteurs
WO2001057074A1 (fr) * 2000-02-04 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands des recepteurs de la classe fpr qui induisent une reponse immunitaire de l'hote a un agent pathogene ou inhibent l'infection par le vih
WO2003074069A2 (fr) * 2002-03-07 2003-09-12 Bayer Healthcare Ag Diagnostic et therapeutique destines a des maladies associees au recepteur peptidique n-formyl 1 (fpr1)
WO2003106683A1 (fr) * 2002-06-14 2003-12-24 武田薬品工業株式会社 Procede de criblage
EP1514930A1 (fr) * 2002-06-14 2005-03-16 Takeda Pharmaceutical Company Limited Procede de criblage
WO2004027427A1 (fr) * 2002-09-19 2004-04-01 Astrazeneca Ab Analyse de ligands fprl-1
WO2005024057A1 (fr) * 2003-09-10 2005-03-17 Galapagos Genomics N.V. Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CUI Y ET AL: "Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease", JOURNAL OF LEUKOCYTE BIOLOGY 01 OCT 2002 UNITED STATES, vol. 72, no. 4, 1 October 2002 (2002-10-01), pages 628 - 635, XP009047055, ISSN: 0741-5400 *
DENG X ET AL: "A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 94, no. 4, 15 August 1999 (1999-08-15), pages 1165 - 1173, XP002154093, ISSN: 0006-4971 *
GEWIRTZ ANDREW T ET AL: "Mechanisms of active intestinal inflammation and potential down-regulation via lipoxins.", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY. 2002, vol. 507, 2002, pages 229 - 236, XP009047056, ISSN: 0065-2598 *
GRONERT K ET AL: "Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 187, no. 8, 20 April 1998 (1998-04-20), pages 1285 - 1294, XP002226394, ISSN: 0022-1007 *
KLEIN C ET AL: "Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 16, no. 13, December 1998 (1998-12-01), pages 1334 - 1337, XP002137534, ISSN: 1087-0156 *
LE Y ET AL: "Formyl-peptide receptors revisited", TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 23, no. 11, 1 November 2002 (2002-11-01), pages 541 - 548, XP004388300, ISSN: 1471-4906 *
LE Y ET AL: "PLEIOTROPIC ROLES OF FORMYL PEPTIDE RECEPTORS", CYTOKINE AND GROWTH FACTOR REVIEWS, OXFORD, GB, vol. 12, no. 1, March 2001 (2001-03-01), pages 91 - 105, XP001133719, ISSN: 1359-6101 *
LE Y ET AL: "Receptors for chemotactic formyl peptides as pharmacological targets", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 2, no. 1, January 2002 (2002-01-01), pages 1 - 13, XP002249587, ISSN: 1567-5769 *
LE Y ET AL: "The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 166, no. 3, 1 February 2001 (2001-02-01), pages 1448 - 1451, XP002973363, ISSN: 0022-1767 *
MADERNA P ET AL: "INFLUENCE OF LIPOXIN A4 AND OTHER LIPOXYGENASE-DERIVED EICOSANOIDS ON TISSUE FACTOR EXPRESSION", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 279, no. 4, PART 1, 2000, pages C945 - C953, XP008003788, ISSN: 0002-9513 *
MURPHY P M ET AL: "A STRUCTURAL HOMOLOGUE OF THE N FORMYL PEPTIDE RECEPTOR CHARACTERIZATION AND CHROMOSOME MAPPING OF A PEPTIDE CHEMOATTRACTANT RECEPTOR FAMILY", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 267, no. 11, 15 April 1992 (1992-04-15), pages 7637 - 7643, XP002137531, ISSN: 0021-9258 *
SERHAN C N: "Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution", PROSTAGLANDINS, BUTTERWORTH, STONEHAM, MA, US, vol. 68-69, August 2002 (2002-08-01), pages 433 - 455, XP004380640, ISSN: 0090-6980 *
WANG J ET AL: "THE INVOLVEMENT OF THE G-PROTEIN COUPLED RECEPTOR FPRL1 IN PROINFLAMMATORY ASPECTS OF ALZHEIMER'S DISEASE", FASEB JOURNAL (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), BETHESDA, US, vol. 15, no. 4, 31 March 2001 (2001-03-31), pages A682, XP008027947, ISSN: 0892-6638 *
YAZAWA HIROSHI ET AL: "beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages", FASEB JOURNAL (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), BETHESDA, US, vol. 15, no. 13, November 2001 (2001-11-01), pages 2454 - 2462, XP002280686, ISSN: 0892-6638 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101724765B1 (ko) 2009-05-18 2017-04-07 액테리온 파마슈티칼 리미티드 Ａｌｘ 수용체 및/또는 ｆｐｒｌ2 아고니스트로서의 브릿지 스피로［2.4］헵탄 유도체

Also Published As

Publication number Publication date
CA2544983A1 (fr) 2005-05-26
EP1692502A2 (fr) 2006-08-23
AU2004290368A1 (en) 2005-05-26
JP2007516434A (ja) 2007-06-21
KR20060130064A (ko) 2006-12-18
WO2005047899A2 (fr) 2005-05-26
BRPI0416272A (pt) 2007-01-09

Similar Documents

Publication Publication Date Title
WO2005047899A3 (fr) Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations
WO2004006853A3 (fr) Traitement et prevention a l'aide d'agents fixant 4-1bb
TW200507830A (en) Bronchodilating β -agonist compositions and methods
EP1737453A4 (fr) Procedes d'utilisation et compositions comprenant des composes destines au traitement et a la gestion de maladies ou de troubles de la peau
WO2005034998A3 (fr) Procedes et compositions destines au traitement de la douleur et d'autres etats a mediation adrenergique alpha-2
WO2006041800A3 (fr) 5-phenoxyalkoxypsoralenes et procedes d'inhibtion selective du canal potassique kv1.3 a tension commandee
AU2003286567A1 (en) Methods for the treatment of skin disorders
WO2006040688A3 (fr) Procede pour traiter des maladies de peau
EP1727530A4 (fr) Formulations topiques pour le traitement d'etats dermatologiques
EP1761266A4 (fr) Composes, preparations et methodes permettant de traiter ou de prevenir des troubles inflammatoires cutanes
HK1090282A1 (en) Use of brimonidine for preventing and reducing the severity of stress- associated conditions
WO2007061661A3 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
WO2005037323A3 (fr) Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines
WO2004093814A3 (fr) Compositions a base d'un inhibiteur selectif de la cyclooxygenase-2 et d'un bloqueur du canal d'ions sodium pour le traitement de la douleur, de l'inflammation ou de troubles medies par l'inflammation
WO2006012641A3 (fr) Procedes de detection et de traitement de troubles auto-immuns
WO2004012762A3 (fr) Methode et composition pour la protection du tissu neuronal contre une lesion induite par des taux de glutamate eleves
WO2007048019A3 (fr) Systeme d'administration d'agents de diagnostic et therapeutiques
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
WO2010059554A3 (fr) Composition et procédé pour le traitement des ecchymoses
WO2005027977A3 (fr) Compositions de diclofenac destinees au traitement d'affections cutanees
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
EP1514539A3 (fr) Analgesique topique microencapsule pour soulager la douleur et manchon le contenant
WO2005013911A3 (fr) Usages protecteurs et therapeutiques de tocotrienols
WO2005123777A3 (fr) Procede de traitement du granulome annulaire ou sarcoide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480036284.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/005109

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2544983

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006539672

Country of ref document: JP

Ref document number: 2557/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004290368

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004810415

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067011178

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2004290368

Country of ref document: AU

Date of ref document: 20041104

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004290368

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004810415

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067011178

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0416272

Country of ref document: BR